MONDAY, Sept. 25, 2023 — For patients with resectable non-small cell lung cancer (NSCLC), combination immunotherapy with the anti-programmed death-ligand 1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the…Original Article
Combo Immunotherapy With Durvalumab Effective for NSCLC
MONDAY, Sept. 25, 2023 — For patients with resectable non-small cell lung cancer (NSCLC), combination immunotherapy with the anti-programmed death-ligand 1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the…
